SBIR-STTR Award

Nnos-Psd95 Inhibitors as Novel Treatments for Tbi
Award last edited on: 6/9/2017

Sponsored Program
SBIR
Awarding Agency
NIH : NINDS
Total Award Amount
$267,381
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Yvonne Y Lai

Company Information

Anagin

1800 North Capitol Avenue
Indianapolis, IN 46202
   (317) 274-5935
   N/A
   www.anagin.com
Location: Single
Congr. District: 07
County: Marion

Phase I

Contract Number: ----------
Start Date: ----    Completed: ----
Phase I year
2016
Phase I Amount
$267,381
This application "nNOS-PSD95 inhibitors as novel treatments for TBI" addresses the critical need for an efficacious treatment for traumatic brain injury (TBI). TBI is the leading cause of death and disability in the most active population (

Public Health Relevance Statement:


Public Health Relevance:
Traumatic brain injury (TBI) is the leading cause of death and disability, with no effective treatment. This proposal seeks to test novel small molecule inhibitor that specifically disrupt a major neuronal signaling pathway in a preclinical model of TBI. If successful, this project will validate a novel approach for the treatment of TBI.

Project Terms:
Address; Adverse effects; Afghanistan; Age-Years; analog; Auditory; base; behavior measurement; Binding (Molecular Function); Blast Cell; brain tissue; Businesses; Caring; Cause of Death; Child; chronic pain; Clinical; cognitive function; Complex; conditioned fear; cost; Coupled; Coupling; Development; Devices; disability; Dose; drug development; Economics; effective therapy; Enzymes; Epilepsy; Excitatory Amino Acid Antagonists; excitotoxicity; Family; Future; Glutamate Receptor; Glutamates; high throughput screening; Hour; Hyperalgesia; Impaired cognition; Impairment; improved; In Vitro; in vivo; Indiana; inhibitor/antagonist; Injury; innovation; Intervention; Iraq; Ischemia; Knowledge; Lead; Measures; Medical; medical schools; Memory; Methods; Modality; Modeling; Molecular; Mortality Vital Statistics; Motor; mouse model; Movement; Mus; N-Methyl-D-Aspartate Receptors; N-Methylaspartate; nerve injury; Nervous System Trauma; Neurologic; neuron loss; Neurons; neurotransmission; Nitric Oxide; Nitric Oxide Synthase Type I; novel; novel strategies; Patients; Pharmacologic Substance; Phase; Phosphorylation; Population; Positioning Attribute; Post-Traumatic Stress Disorders; postsynaptic density protein; Pre-Clinical Model; prevent; Production; programs; protein complex; protein protein interaction; public health relevance; Receptor Activation; Receptor Signaling; Recovery; Recovery of Function; Research; Role; Scaffolding Protein; Signal Pathway; Signal Transduction; Signaling Molecule; Small Business Innovation Research Grant; small molecule; small molecule inhibitor; social; Societies; statistics; Testing; Therapeutic; Time; Translating; Traumatic Brain Injury; treatment response; United States; Universities; Veterans; War; Work; young adult

Phase II

Contract Number: ----------
Start Date: ----    Completed: ----
Phase II year
----
Phase II Amount
----